ArticleDiscover oncology2026
Age-stratified analysis of invasive lobular carcinoma reveals comparable clinicopathological and molecular features across age groups.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Age-Associated Four-Gene Prognostic Signature in Breast Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeYoung-onset breast cancer (YOBC) is generally associated with aggressive behavior and poor prognosis. Young-onset invasive lobular carcinoma (Y-ILC) is rare, and its clinicopathological and molecular features remain unclear. This study aimed to clarify its characteristics using public datasets.
methodsClinical, pathological, survival and genomic data for invasive lobular carcinoma (ILC) were collected from The Cancer Genome Atlas, Molecular Taxonomy of Breast Cancer International Consortium and Memorial Sloan Kettering Cancer Center databases. Patients were classified into three age groups: Y-ILC (≤ 45 years), middle-aged ILC (M-ILC, 46–69 years) and older ILC (O-ILC, ≥ 70 years). Comparative analyses of clinicopathological features, survival outcomes and genetic profiles were performed among the three cohorts.
resultsY-ILC accounted for only 5.4% of YOBC cases, confirming its rarity. Among 402 ILC cases, 30 (7.5%) were Y-ILC, 259 (64.4%) M-ILC and 113 (28.1%) O-ILC. No significant differences in clinicopathological parameters were observed among the three age groups. Survival analysis revealed significant differences in 5- and 10-year overall survival and restricted mean survival time among the groups, with O-ILC showing markedly poorer outcomes. Y-ILC tended to show higher frequencies of BRCA1 and CASP8 mutations, while copy number alterations in FGF4, FGF19 and CCND1 increased progressively with age.
conclusionsY-ILC is rare and clinically comparable to ILC in older age groups, showing broadly similar molecular profiles with subtle age-related differences. Although YOBC is generally viewed as high-risk, Y-ILC did not demonstrate inferior survival; rather, survival deterioration was confined to the older cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.